Cure My Disease

Don't miss your cure!

 Log in / Sign up

Yogurt as medicine? Butyrate-Rich formula tested for Cancer-Related constipation

NCT ID NCT07723729

Symptom relief Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase II trial investigates whether a specially formulated yogurt rich in butyrate—a short-chain fatty acid—can relieve constipation in people with gastrointestinal cancer. Constipation is a common and distressing side effect of cancer and its treatments, and current medications often fall short. The yogurt is designed to improve gut motility, strengthen the intestinal barrier, and restore healthy gut bacteria. The study will enroll 30 participants to measure how well the yogurt works and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a butyrate-containing short-chain fatty acid yogurt (dietary supplement)
What this could lead to
If effective, this yogurt could offer a well-tolerated, food-based option to manage constipation in cancer patients, improving quality of life without the side effects of laxatives.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The yogurt's effect may be modest, and individual responses could vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years. 2. Histologically confirmed diagnosis of gastrointestinal malignancy. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 4. Confirmed \< 3 spontaneous bowel movements (CSBM) per week during the 1-week baseline period, accompanied by constipation-related symptoms (e.g., straining, hard/lumpy stools, sensation of incomplete evacuation, etc.). 5. Anticancer treatment regimen is expected to remain relatively stable during the study period. 6. Willing and able to provide written informed consent and complete electronic diary entries. Exclusion Criteria: 1. Mechanical intestinal obstruction, active inflammatory bowel disease, severe rectal stricture, or acute abdomen. 2. Absolute neutrophil count (ANC) \< 1.0 × 10⁹/L or active infection. 3. New initiation or major dose adjustment of prosecretory or prokinetic agents within the past 2 weeks. 4. Allergy or hypersensitivity to dairy products or any component of the butyrate-containing yogurt formulation. 5. Deemed unsuitable for enrollment by the investigator (e.g., poor compliance, cognitive impairment, or other conditions that may interfere with study participation).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Constipation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

constipation disorder digestive system cancer digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Constipation Gastrointestinal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.